The proteins CD47 and SIRPα are fundamental to establishing a correct number of immune cells, so-called B lymphocytes. This according to a dissertation by Shrikant Shanital Kolan from Umeå University in Sweden.
Sep 22, 2015
0
16
Eight of 14 patients in the first trial of the University of Pennsylvania's personalized cellular therapy for chronic lymphocytic leukemia (CLL) responded to the therapy, with some complete remissions continuing past four ...
Sep 2, 2015
0
862
Monash researchers have uncovered the mechanism used by a common type of blood cancer to hide itself from the immune system.
Aug 11, 2015
0
42
The costs associated with cancer drug prices have risen dramatically over the past 15 years, which is of concern to many top oncologists. In a new analysis, researchers at The University of Texas MD Anderson Cancer Center ...
Jun 23, 2015
0
18
Modifying the small white blood cells that protect against disease might help treat immune disorders, according to a study1 published in Cellular and Molecular Gastroenterology and Hepatology, the basic science journal of ...
Jun 15, 2015
0
8
The move to make cancer treatments gentler for children has paid a double dividend: More kids are surviving than ever before, and without the long-term complications that doomed many of their peers a generation ago, new research ...
Jun 1, 2015
0
78
Because of the significant benefit found in combining the targeted drug ibrutinib with standard chemotherapy for relapsed chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), an interim analysis has closed ...
May 30, 2015
0
12
(HealthDay)—Articles relating to malignant hematology, transfusion medicine, and bleeding and clotting disorders are included in a special update summary published online April 30 in the Annals of Internal Medicine.
May 8, 2015
0
19
Two new cancer studies out of Dalhousie Medical School have shown success in testing safer, less toxic treatments for a rare form of pediatric leukemia called T-cell acute lymphocytic leukemia (T-ALL). The studies were published ...
Apr 17, 2015
0
34
Almost all patients with a group of blood cancers called B-cell malignancies have two prominent "fingerprints" on the surface of leukemia and lymphoma cancers, called CD22 and CD19, Vallera explained. To develop the drug, ...
Mar 13, 2015
0
8
